Atomico’s Biotech Startup Labgenius Raises A £35m Series B

LabGenius, a UK drug discovery startup, has raised £35m in funding to further develop their machine learning-driven platform for creating antibody therapies to treat cancer. The company’s platform uses active learning to design molecules that limit damage to healthy cells, making it more effective than conventional treatment methods. LabGenius aims to use the funding to expand their platform, form strategic partnerships, and invest in drug development for solid tumours.